Non-valvular atrial fibrillation
Conditions
Interventions
Educational Program for the DOAC use
Regular medication instruction
Sponsors
Tokyo Women's Medical University
Tokyo Women'
s Medical University Yachiyo Medical Center National Hospital Organization Yokohama Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 NVAF patients in outpatient clinics 2 Patients taking edoxaban or apixaban for more than 4 weeks prior to enrolling in this trial 3 In participating in this study, patients who received written consent
Exclusion criteria
Exclusion criteria: 1 Patients participating in or participating in other clinical trials 2 Patients who are considered difficult to examine medication adherence 3 Patients requiring family member or others supports with medication management 4 Inpatients 5 Patients were pregnant or expecting to become pregnant within the duration of the study 6 Patients judged unsuitable as research subjects by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adherence difference estimated by the electronic monitoring device between the observation and intervention periods (each period for 12 weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| Adherence estimated by the electronic monitoring device during the observation p3riod (12 weeks) | — |
Countries
Japan
Contacts
Public ContactTsuyoshi Shiga
Tokyo Women's Medical University Cardiology
Outcome results
None listed